注册以创建品种、
财经事件和所关注作者内容的提醒
免费注册 已有账户? 登录
Tango Therapeutics Inc是一家精准肿瘤学公司,致力于发现和开发针对未满足医疗需求的患者的肿瘤抑制基因丢失的药物。该公司的候选产品包括TNG908和泛素特异性蛋白酶1(USP1)。TNG908是一种合成的致死小分子蛋白精氨酸甲基转移酶5(PRMT5)抑制剂,旨在选择性地在甲基硫腺苷磷酸化酶(MTAP)缺失的癌细胞中发挥作用。MTAP缺失发生在所有人类肿瘤中,包括非小细胞肺癌(NSCLC)、间皮瘤、胰腺癌、胆管癌和胶质母细胞瘤。该公司专注于启动I/II期临床试验。USP1是BRCA1突变乳腺癌的合成致命靶点发现筛选。该公司的先导分子在BRCA2突变患者衍生的异种移植物中也具有活性,包括对聚合酶(PARP)抑制具有内在抗性的BRCA1和BRCA2突变模型。
名称 | 年龄 | 任期 | 标题 |
---|---|---|---|
Carole L. Nuechterlein | 59 | 2020 | Independent Director |
Aaron I. Davis | 43 | 2020 | Chairman & CEO |
James G. Christensen | 53 | 2020 | Independent Director |
Charles M. Baum | 63 | 2020 | Independent Director |
Christopher Fuglesang | 52 | 2020 | President & Director |
Richard A. Heyman | 64 | - | Independent Director |
James B. Avery | 58 | 2020 | Independent Director |
Barbara L. Weber | 67 | 2017 | President, CEO & Director |
Alexis A. Borisy | 51 | 2017 | Independent Chairman |
Malte Peters | 61 | 2018 | Independent Director |
John G. Doench | - | 2021 | Member of Scientific Advisory Board |
Mace L. Rothenberg | 66 | 2021 | Independent Director |
Lesley Ann Calhoun | 57 | 2021 | Independent Director |
Ulrich Elling | - | 2021 | Member of Scientific Advisory Board |
John Ketchum | - | 2023 | Independent Director |
Kanishka Ram Pothula | 39 | 2023 | Independent Director |
Antoni Ribas | 57 | 2021 | Founder & Member of Scientific Advisory Board |
Alan Ashworth | 63 | 2021 | Founder & Member of Scientific Advisory Board |
William G. Kaelin | 66 | 2021 | Founder & Member of Scientific Advisory Board |
确定屏蔽%USER_NAME%?
如果屏蔽,您和%USER_NAME%都无法看到相互在Investing.com上发布的信息。
%USER_NAME%已成功添加至屏蔽列表
由于您刚刚取消屏蔽此人,因此必须等待48小时才能重新屏蔽。
您举报该评论的原因为:
谢谢您!
您的举报将会被发送到管理员进行审核